Patient characteristics
| . | Overall no. of patients (%) . | p53 negative . | p53 positive . | P . |
|---|---|---|---|---|
| Total | 48 | 20 | 28 | |
| Age (y) | ||||
| <50 | 28 (58) | 9 (45) | 19 (68) | |
| >50 | 20 (42) | 11 (55) | 9 (32) | 0.11 |
| Race | ||||
| Asian | 2 (4) | 1 (5) | 1 (4) | |
| Black | 3 (6) | 1 (5) | 2 (7) | |
| Hispanic | 6 (13) | 3 (15) | 3 (11) | |
| Caucasian | 37 (77) | 15 (75) | 22 (79) | 0.43 |
| Lymphovascular invasion | ||||
| No | 2 (6) | 0 (0) | 2 (12) | |
| Yes | 29 (94) | 14 (100) | 15 (88) | 0.49 |
| Nuclear grade | ||||
| 2 | 11 (24) | 7 (39) | 4 (15) | |
| 3 | 34 (76) | 11 (61) | 23 (85) | 0.09 |
| Histology | ||||
| Ductal | 41 (89) | 16 (84) | 25 (93) | |
| Lobular | 4 (9) | 3 (16) | 1 (4) | |
| Metaplastic | 1 (2) | 0 (0) | 1 (4) | 0.29 |
| ER | ||||
| Negative | 32 (58) | 9 (47) | 23 (64) | |
| Positive | 23 (42) | 10 (53) | 13 (36) | 0.003 |
| PR | ||||
| Negative | 37 (82) | 13 (68) | 24 (92) | |
| Positive | 8 (18) | 6 (32) | 2 (8) | 0.05 |
| Taxane use | ||||
| No | 10 (21) | 5 (25) | 5 (18) | |
| Yes | 38 (79) | 15 (75) | 23 (82) | 0.72 |
| pCR | ||||
| Yes | 9 (19) | 4 (20) | 5 (18) | |
| No | 39 (81) | 16 (80) | 23 (82) | 1.00 |
| . | Overall no. of patients (%) . | p53 negative . | p53 positive . | P . |
|---|---|---|---|---|
| Total | 48 | 20 | 28 | |
| Age (y) | ||||
| <50 | 28 (58) | 9 (45) | 19 (68) | |
| >50 | 20 (42) | 11 (55) | 9 (32) | 0.11 |
| Race | ||||
| Asian | 2 (4) | 1 (5) | 1 (4) | |
| Black | 3 (6) | 1 (5) | 2 (7) | |
| Hispanic | 6 (13) | 3 (15) | 3 (11) | |
| Caucasian | 37 (77) | 15 (75) | 22 (79) | 0.43 |
| Lymphovascular invasion | ||||
| No | 2 (6) | 0 (0) | 2 (12) | |
| Yes | 29 (94) | 14 (100) | 15 (88) | 0.49 |
| Nuclear grade | ||||
| 2 | 11 (24) | 7 (39) | 4 (15) | |
| 3 | 34 (76) | 11 (61) | 23 (85) | 0.09 |
| Histology | ||||
| Ductal | 41 (89) | 16 (84) | 25 (93) | |
| Lobular | 4 (9) | 3 (16) | 1 (4) | |
| Metaplastic | 1 (2) | 0 (0) | 1 (4) | 0.29 |
| ER | ||||
| Negative | 32 (58) | 9 (47) | 23 (64) | |
| Positive | 23 (42) | 10 (53) | 13 (36) | 0.003 |
| PR | ||||
| Negative | 37 (82) | 13 (68) | 24 (92) | |
| Positive | 8 (18) | 6 (32) | 2 (8) | 0.05 |
| Taxane use | ||||
| No | 10 (21) | 5 (25) | 5 (18) | |
| Yes | 38 (79) | 15 (75) | 23 (82) | 0.72 |
| pCR | ||||
| Yes | 9 (19) | 4 (20) | 5 (18) | |
| No | 39 (81) | 16 (80) | 23 (82) | 1.00 |